BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Australia

TGA Approves IFINWIL® for High-Risk Neuroblastoma Treatment in Australia

Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has approved the registration of IFINWIL® (eflornit...

April 17, 2025 | Regulatory

Clarity Begins Phase II Dosing in SECuRE Trial for Prostate Cancer with Enhanced 67Cu-SAR-bisPSMA Formulation

The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GB...

April 16, 2025 | News

Telix Reports Positive Preliminary Results from IPAX-Linz Study of TLX101 in Recurrent High-Grade Glioma

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101&nb...

April 16, 2025 | News

Atmo Biosciences Secures Full Ownership of Core IP for Ingestible Gas-Sensing Capsule

Atmo secures full ownership of core IP for its ingestible gas-sensing capsule • RMIT University transfers all patents and IP in exchange for an eq...

April 15, 2025 | News

Telix Doses First Patient in ZOLAR Phase 1 Trial for Advanced Soft Tissue Sarcoma

Telix Pharmaceuticals Limited announces that a first patient has been dosed in the Phase 1 ZOLAR trial of TLX300-CDx (89Zr-olaratumab) in patients wit...

April 02, 2025 | News

Ractigen Reports Promising Phase I Data for First-in-Class saRNA Therapy RAG-01 in Bladder Cancer

Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, announced the presentation of...

March 25, 2025 | News

Parse Biosciences Welcomes South Australian Genomics Centre as First Certified Service Provider in Asia-Pacific

Parse Biosciences, a leader in scalable and affordable single-cell sequencing, is delighted to welcome the South Australian Genomics Centre (SAGC)&nbs...

March 24, 2025 | News

Telix Secures FDA Approval for Gozellix® to Expand PSMA-PET Imaging Access in Prostate Cancer

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administrat...

March 21, 2025 | News

Alamar Biosciences Expands APAC Presence with Five New Distribution Partnerships

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce the signing of five new dis...

March 20, 2025 | News

Telix and R2PHARMA Secure ANVISA Approval for Illuccix®, Expanding PSMA-PET Imaging in Brazil

Telix Pharmaceuticals Limited announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approv...

March 19, 2025 | News

Exicure Secures Australian Patent for Dual-Target Cancer Therapy Approach

Exicure, Inc. announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." ...

March 14, 2025 | News

Telix Pharmaceuticals Develops High-Yield Lead-212 Generator to Advance Targeted Alpha Therapy

Telix Pharmaceuticals Limited announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb...

March 13, 2025 | News

Advancing Cell & Gene Therapy in APJ: How Thermo Fisher Enables Breakthrough Innovation

What are the most significant recent breakthroughs in cell and gene therapy and how is Thermo Fisher Scientific involved in these advancements? In 2024, t...

March 14, 2025 | Interaction

Japan Grants Orphan Drug Designation to Lundbeck’s Amlenetug for Multiple System Atrophy

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetu...

March 11, 2025 | News

Stay Connected